| [September 26, 2007] |
 |
Sequenom Announces Commercial Launch of New Assay Design and Validation Service and Online Customer Portal
SAN DIEGO --(Business Wire)-- Sequenom, Inc. (NASDAQ:SQNM), a leading provider of fine mapping genotyping, methylation and gene expression analysis solutions, today announced the commercial launch of its Assays-By-Sequenom(TM) service. This service provides customers with the flexibility to choose any SNP of interest combined with the convenience and reliability of off-the-shelf pre-validated assay reagents. The new offering includes assay design for customer specified SNPs along with delivery of ready-to-use functionally validated assays for use with the MassARRAY(R) platform.
"We listened to increased customer demand for ready-to-go multiplexed genotyping assays," said Michael Monko, Senior Vice President of Sales and Marketing at Sequenom. "Our turnkey solution is Assays-By-Sequenom, a service that enables fast experimental turnaround time by delivering easy to order, ready-to-go, custom designed multiplexed assays."
The new offering includes three levels of service; the levels range from basic assay design and oligonucleotide pooling to delivery of validated multiplexed assays. Customers will also receive ready-to-go oligonucleotide mixes and assay design files for import into the MassARRAY platform's Typer 4.0 software. This added convenience decreases hands-on time and infrastructure requirements for assay set up. MassARRAY customers will be able to access this service through a new customer portal called MySequenom.com that also offers additional tools and download options, e-commerce capabilities and support functions.
"This service offering complements our recently launched iPLEX(TM) Gold assay by providing a convenient solution for the assay set up of highly multiplexed genotyping assays," said Harry Stylli, Ph.D., President and Chief Executive Officer of Sequenom. "We expect this service to enable researchers to perform larger scale studies with faster turnaround time, further strengthening our competitive advantage in the SNP fine mapping market."
About Sequenom
Sequenom is committed to providing the best genetic analysis products that translate genomic science into superior solutions for biomedical research, livestock and agricultural applications, molecular medicine, and non-invasive prenatal testing. The Company's proprietary MassARRAY system is a high-performance DNA analysis platform that efficiently and precisely measures the amount of genetic target material and variations therein. The system is able to deliver reliable and specific data from complex biological samples and from genetic target material that is only available in trace amounts. The Company has exclusively licensed intellectual property rights for the development and commercialization of non-invasive prenatal genetic tests for use with the MassARRAY system and other platforms.
Sequenom(R) and MassARRAY(R) and Assays-By-Sequenom(TM) are trademarks of Sequenom, Inc.
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding customer demand for ready to go multiplexed genotyping assays, the Company's expectations for Assays-By-Sequenom including its ability to enable researchers to perform larger scale studies with faster turnaround time and to strengthen the Company's competitive advantage in the SNP fine mapping market, and commercializing non-invasive prenatal genetic tests, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with new technology and product development and commercialization, customer acceptance of and demand for new services and products such as Assays-By-Sequenom, and other risks detailed from time to time in the Company's SEC (U.S. Securities and Exchange Commission) filings, including the Company's Annual Report on Form 10-K for the year ended December 31, 2006, most recent periodic quarterly report, and other documents subsequently filed with or furnished to the SEC. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
[ Back To TMCnet.com's Homepage ]
|
INDUSTRIES
Activate Email 
INDUSTRIES
Find Solutions for Enterprises, SMBs & Service Providers at the INTERNET TELEPHONY Conference and EXPO West, September 1-3, 2009. Los Angeles, CA.
